Weight loss patient in East Valley AZ using GLP-1 weight loss medication.

Cardiologists & GLP-1 for Weight Loss


 Obesity is more than simply excess weight – it’s a major risk factor for heart disease, stroke, diabetes, and a host of chronic conditions. Historically, doctors have urged patients to try diet, exercise, and behavior change first, only turning to medications or surgery when those efforts failed. But that paradigm is shifting. In mid-2025, the American College of Cardiology released Concise Clinical Guidance, urging cardiologists and other clinicians to embrace GLP-1 receptor agonists (such as semaglutide, liraglutide, and tirzepatide) as first-line tools in obesity care, especially for patients at cardiovascular risk. 

Rather than making patients “fail first,” the guidance suggests that when obesity is a comorbidity, early use of GLP-1 therapies makes sense alongside lifestyle intervention. 

How GLP-1 Therapies Work & Cardiovascular Benefits

Someone holding a bottle of Ozempic in Mesa, AZ.GLP-1 receptor agonists (GLP-1 RAs) mimic the hormone glucagon-like peptide-1, which is secreted naturally in the gut. These medications slow gastric emptying, boost satiety, and reduce appetite. Over time, many patients lose 10–15 % or more of their body weight. 

But their cardiovascular effects go beyond just weight reduction. Clinical trials have shown that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE: nonfatal heart attack, nonfatal stroke, or cardiovascular death). These benefits are thought to stem not only from weight loss, but also from favorable metabolic effects (improved glucose control, reduced inflammation, better lipid profiles) and direct vascular effects. 

In fact, the new guidance cites growing evidence that GLP-1 therapy should be considered in patients with heart failure and obesity (especially HFpEF), conditions in which traditional weight loss modalities often struggle to produce durable results. 

What the ACC’s New Guidance Says & Why It Matters

 In the 2025 Concise Clinical Guidance, the ACC states that weight management must become a core part of cardiovascular care. The guidance explicitly encourages clinicians to “consider GLP-1 receptor agonists in eligible patients” rather than deferring medication until lifestyle efforts fail.

This is a notable shift: obesity and metabolic risk are no longer secondary issues to be managed after cardiac problems – they are central to cardiovascular risk management. 

Why the change now? Because the clinical evidence has matured, with robust trials, real-world studies, and meta-analyses demonstrating consistent benefit in both weight loss and cardiovascular outcomes.

For patients in Phoenix, Mesa, and southern Arizona, this means that medical weight loss practices (like ours at New Results) are increasingly aligned with cardiology standards – not just aesthetic or wellness programs.

Practical Considerations, Eligibility & Monitoring

Client getting injected with a GLP-1.

GLP-1 therapy isn’t appropriate for everyone, and safe use requires medical supervision. Key considerations include:

  • Eligibility: Most guidelines consider GLP-1 RAs for patients with BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with weight-related comorbidities).

  • Contraindications: History of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy, or severe gastrointestinal disease may be exclusion criteria.

  • Side Effects: Common side effects include nausea, vomiting, and GI discomfort. Long-term use may lead to muscle loss in inactive individuals, so concurrent resistance exercise and protein intake are crucial.

  • Monitoring: Regular follow-up is necessary to adjust the dosage, monitor for side effects, assess metabolic markers, and ensure patient safety.

  • Supportive Therapies: Nutritional counseling, behavioral therapy, exercise plans, sleep and stress optimization are essential complements. The new guidance emphasizes that GLP-1 should not be used in isolation.

At our clinics in Mesa and Phoenix, we thoroughly screen patients, tailor dosing protocols, and integrate lifestyle support from the start.

What This Means for You in Mesa & Phoenix + Conclusion


 If you live in the Valley region (Mesa, Phoenix, or nearby), here’s what the new cardiology-endorsed approach means for you:

  • You no longer have to “fail first” with lifestyle-only attempts before qualifying for medical treatment.

  • Using GLP-1 therapy under medical supervision can offer dual benefits: weight loss and improved heart health.

  • In Phoenix/Mesa, clinics like New Results Medical Weight Loss are ideally positioned to deliver this integrated approach – combining endocrinology, cardiometabolic insight, nutrition, and lifestyle medicine.

  • If you have obesity, elevated cardiovascular risk (hypertension, dyslipidemia, prediabetes, insulin resistance), or concerns about heart disease, it may be well worth discussing GLP-1 options with your provider.


The landscape for weight loss and cardiovascular prevention is shifting. What was once a reactive, secondary treatment is now being embraced by cardiologists as foundational in obesity care. For residents of Phoenix and Mesa, this offers a timely opportunity: medically supervised, evidence-based therapy that treats the body holistically – not just a number on the scale.

If you’d like to learn more about whether GLP-1 therapy is appropriate for you, or how New Results Medical Weight Loss approaches this in Phoenix/Mesa, contact us for a consultation.